Compositions and methods for inhibiting beta amyloid secretion

A method for inhibiting amyloid β peptide secretion in a subject, the method comprising:

• administering to the subject a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition including a compound having the formula (I):
• where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group;
• p is an integer from 0-3;
• X1 is a 3-9 atoms in length linker connecting A and B;
• B is selected from a substituted or unsubstituted aryl, alkoxy or amine group;
• and
• a pharmaceutically acceptable salt thereof;
• and a pharmaceutical carrier.

A method for treating a neurological or neurodegenerative disorder in a subject, the method comprising:

• administering to the subject a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition including a compound having the formula (I):
• where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group;
• p is an integer from 0-3;
• X1 is a 3-9 atoms in length linker connecting A and B;
• B is selected from a substituted or unsubstituted aryl, alkoxy or amine group;
• and
• a pharmaceutically acceptable salt thereof;
• and a pharmaceutical carrier.